In a report released today, Joseph Stringer from Needham maintained a Buy rating on Phathom Pharmaceuticals, with a price target of $28.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Joseph Stringer has given his Buy rating due to a combination of factors including Phathom Pharmaceuticals’ strong financial performance in the third quarter of 2025. The company reported higher-than-expected revenue from its Voquezna product, surpassing both the firm’s estimates and the consensus forecast. Additionally, the company’s operating expenses were lower than anticipated, aligning with management’s goal of achieving profitability by 2026.
Furthermore, the positive quarterly results prompted Phathom to raise its lower-end revenue guidance for 2025 and reduce its non-GAAP operating expense forecast. The successful launch of Voquezna continues to show promising growth metrics, and management’s efforts to streamline expenses have been effective. Given these developments, Stringer believes the stock is currently undervalued and recommends buying on strength.
Stringer covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Moderna, and Avidity Biosciences. According to TipRanks, Stringer has an average return of 17.6% and a 46.61% success rate on recommended stocks.